SUN Xinzhao, LUO Yanlu, FAN Jiangtao, ZHONG Xueyan. Expression of STAT3 in endometrial carcinoma and its clinicopathological significance[J]. Basic & Clinical Medicine, 2023, 43(10): 1577-1579.
[1]Urick ME, Bell DW. Clinical actionability of molecular targets in endometrial cancer[J]. Nat Rev Cancer, 2019, 19: 510-521. [2]Zou S, Tong Q, Liu B, et al. Targeting STAT3 in cancer immunotherapy[J]. Mol Cancer, 2020, 19: 145.doi: 10.1186/s12943-020-01258-7. [3]Liu Y, Liao S, Bennett S, et al. STAT3 and its targeting inhibitors in osteosarcoma[J]. Cell Prolif, 2021, 54: e12974. doi: 10.1111/cpr.12974. [4]Yang X, Lin Y, Shi Y, et al. FAP promotes immunosuppression by cancer-associated fibroblasts in the tumor microenvironment via STAT3-CCL2 signaling [J]. Cancer Res, 2016, 76: 4124-4135.